Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
20.6M
-
Shares change
-
+779K
-
Total reported value, excl. options
-
$426M
-
Value change
-
+$18.6M
-
Put/Call ratio
-
1.64
-
Number of buys
-
42
-
Number of sells
-
-24
-
Price
-
$20.73
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2015
81 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2015.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.6M shares
of 105M outstanding shares and own 19.66% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4.59M shares), FRANKLIN RESOURCES INC (3.4M shares), NQ HCIF GP, Ltd. (3.1M shares), JPMORGAN CHASE & CO (1.22M shares), Bank of New York Mellon Corp (1.16M shares), Visium Asset Management, LP (1.12M shares), Polar Capital LLP (1.11M shares), Arrowpoint Asset Management, LLC (834K shares), BlackRock Fund Advisors (542K shares), and VANGUARD GROUP INC (418K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.